8-K: UroGen Pharma Launches ZUSDURI, Reports Q2 2025 Results

UroGen Pharma announced the FDA approval and commercial launch of ZUSDURI for recurrent LG-IR-NMIBC, alongside an 11% increase in JELMYTO net product sales to $24.2 million for Q2 2025, despite an increased net loss.

Summary

• The U.S. Food and Drug Administration (FDA) approved ZUSDURI (mitomycin) for intravesical solution on June 12, 2025, making it the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
• JELMYTO (mitomycin) for pyelocalyceal solution generated net product sales of $24.2 million in Q2 2025, an 11% increase compared to $21.8 million in Q2 2024, driven by 7% underlying demand growth and price favorability.
• Cash, cash equivalents, and marketable securities totaled $161.6 million as of June 30, 2025.
• Net loss for the second quarter of 2025 was $49.9 million, or ($1.05) per basic and diluted share, compared to a net loss of $33.4 million, or ($0.82) per basic and diluted share, in Q2 2024.
• Research & Development (R&D) expenses increased to $18.9 million in Q2 2025 from $15.4 million in Q2 2024, primarily due to higher manufacturing costs and costs associated with the Phase 3 UTOPIA trial for UGN-103.
• Selling, General and Administrative (SG&A) expenses increased to $43.2 million in Q2 2025 from $30.1 million in Q2 2024, mainly driven by ZUSDURI commercial preparation activities and overall commercial operation costs.
• Enrollment is complete in the Phase 3 UTOPIA clinical trial of investigational drug UGN-103 for recurrent LG-IR-NMIBC.
• A Phase 3 study has been initiated to explore the safety and efficacy of UGN-104 for LG-UTUC.
• Enrollment is complete in the dose escalation phase of UGN-301 (an anti-CTLA4 antibody) for high-grade non-muscle invasive bladder cancer, demonstrating an acceptable safety profile and observed responses.
• Full-year 2025 net product revenue guidance for JELMYTO remains unchanged at $94 million to $98 million, implying an 8% to 12% year-over-year growth rate.
• Full-year 2025 operating expense guidance remains unchanged at $215 million to $225 million, including $11 million to $14 million in non-cash share-based compensation expense.

Sentiment

Score: 7

Explanation: The FDA approval and commercial launch of ZUSDURI are significant positive catalysts, expanding the company's commercial portfolio and addressing a large market. JELMYTO continues to show solid growth. While net loss increased due to commercialization and R&D investments, this is expected for a growth-stage biotech. The cash position remains strong enough to support current operations and launch activities. The pipeline progress is also encouraging.

Positives

• FDA approval and commercial launch of ZUSDURI, expanding the commercial portfolio and marking the company's evolution into a multi-product uro-oncology company.
• ZUSDURI is the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
• Strong duration of response data for ZUSDURI from the Phase 3 ENVISION trial, showing a 72.2% probability of remaining in complete response at 24-months.
• Positive five-year results from the long-term extension study of the Phase 2b OPTIMA II trial for ZUSDURI, with a median duration of response of approximately 3.5 years.
• JELMYTO net product sales grew 11% year-over-year to $24.2 million in Q2 2025, driven by 7% underlying demand growth.
• Solid balance sheet with $161.6 million in cash, cash equivalents, and marketable securities as of June 30, 2025.
• Completion of enrollment for the Phase 3 UTOPIA trial of UGN-103, a next-generation product designed to offer improvements over ZUSDURI.
• Initiation of a Phase 3 study for UGN-104, a next-generation product for LG-UTUC.
• Completion of the dose escalation phase for UGN-301, with an acceptable safety profile and observed responses in both monotherapy and combination therapy arms.

Negatives

• Net loss increased significantly to $49.9 million in Q2 2025 from $33.4 million in Q2 2024.
• Research & Development expenses increased by $3.5 million in Q2 2025 compared to Q2 2024.
• Selling, General and Administrative expenses increased by $13.1 million in Q2 2025 compared to Q2 2024.
• Interest expense on long-term debt increased to $4.1 million in Q2 2025 from $3.5 million in Q2 2024.
• Cash, cash equivalents, and marketable securities decreased from $241.7 million at December 31, 2024, to $161.6 million at June 30, 2025.
• Total shareholders' deficit increased from $(8.803) million at December 31, 2024, to $(93.376) million at June 30, 2025.

Risks

• Clinical results may not be indicative of results that may be observed in the future, including in larger populations.
• Potential safety and other complications related to UroGen's products.
• Risks related to the company's and its licensors' ability to protect their respective patents and other intellectual property.
• The ability to maintain regulatory approval for products.
• Complications associated with commercialization activities.
• Labeling limitations for approved products.
• Competition in UroGen's industry.
• The scope, progress, and expansion of developing and commercializing UroGen's products and product candidates.
• The size and growth of the market(s) for products and product candidates, and the rate and degree of market acceptance thereof vis-à-vis alternative therapies or procedures, such as surgery.
• The ability to attract or retain key management, members of the board of directors, and other personnel.
• RTGel technology and ZUSDURI may not perform as expected.
• New data relating to ZUSDURI, including from spontaneous adverse event reports and from the ongoing ENVISION trial, may result in changes to the product label and may adversely affect sales, or result in withdrawal of ZUSDURI from the market.
• The potential for payors to delay, limit, or deny coverage for ZUSDURI.
• UroGen may not successfully develop and receive regulatory approval of any other product that incorporates RTGel technology.
• The impacts of general macroeconomic and geopolitical conditions on UroGen's business and financial position.

Future Outlook

UroGen expects full-year 2025 JELMYTO net product revenues to be in the range of $94 million to $98 million, implying an 8% to 12% year-over-year growth. Full-year 2025 operating expenses are projected to be $215 million to $225 million. The company is well-positioned to fully support the launch of ZUSDURI while advancing strategic business initiatives to drive sustained growth and innovation, with continued progress across its pipeline including next-generation mitomycin formulations and immuno-oncology candidates.

Management Comments

• Liz Barrett, President and Chief Executive Officer: "The recent FDA approval of ZUSDURI for the treatment of adults with recurrent LG-IR-NMIBC represents a truly transformative milestone for patients and for UroGen, marking our evolution into a multi-product uro-oncology company and our leadership in the field."
• Liz Barrett, President and Chief Executive Officer: "Our commercial team is enthusiastically executing the ZUSDURI launch plan as we scale the organization to address the estimated $5 billion+ market opportunity."
• Liz Barrett, President and Chief Executive Officer: "JELMYTO (mitomycin) for pyelocalyceal solution, our treatment for low-grade upper tract urothelial carcinoma (LG-UTUC), continues to grow with strong underlying demand in the second quarter reflecting continued interest in this important therapy for patients."
• Liz Barrett, President and Chief Executive Officer: "We are equally excited about the continued progress across our pipeline, including our next-generation mitomycin formulations and immuno-oncology candidates."
• Liz Barrett, President and Chief Executive Officer: "With a solid balance sheet, we are well positioned to fully support the launch of ZUSDURI while advancing strategic business initiatives to drive sustained growth and innovation."

Industry Context

UroGen Pharma is expanding its footprint in the specialized uro-oncology market with the launch of ZUSDURI, positioning itself as a multi-product company. This move allows the company to address the significant estimated $5 billion+ market opportunity for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The company's proprietary RTGel technology offers a differentiated, non-surgical, sustained-release approach for treating urothelial cancers, which could provide a competitive advantage over traditional surgical or systemic chemotherapy options. The continued growth of JELMYTO for low-grade upper tract urothelial carcinoma (LG-UTUC) further solidifies UroGen's niche in less invasive cancer treatments within the broader oncology landscape.

Comparison to Industry Standards

• No specific comparable companies, projects, or results to global benchmarks were mentioned in the filing for direct comparison.

Stakeholder Impact

• Shareholders: Potential for increased revenue and market share due to the ZUSDURI launch, but also increased expenses and net loss in the short term. Long-term value creation depends on successful commercialization and pipeline development.
• Patients: ZUSDURI provides the first and only FDA-approved non-surgical treatment option for recurrent LG-IR-NMIBC, offering a transformative milestone. JELMYTO continues to provide an important therapy for LG-UTUC.
• Employees: Scaling the organization to address the ZUSDURI market opportunity implies potential growth and stability for employees.
• Healthcare Providers: New treatment options (ZUSDURI) and ongoing data collection (uTRACT Registry) provide more tools and insights for managing urothelial cancers.

Next Steps

• Enthusiastically executing the ZUSDURI launch plan and scaling the organization to address the estimated $5 billion+ market opportunity.
• Continued progress across the pipeline, including next-generation mitomycin formulations and immuno-oncology candidates.
• Collection of comprehensive data over a three-year period for the uTRACT Registry study for JELMYTO, with the goal of providing insights into treatment patterns, long-term outcomes, and patient safety in real-world settings.
• Ongoing patient follow-up for UGN-301 to further assess the durability of responses.
• Advancing strategic business initiatives to drive sustained growth and innovation.

Key Dates

Recommendation

The FDA approval and launch of ZUSDURI are significant positive catalysts, positioning UroGen as a multi-product company in a large market. JELMYTO's continued growth is also positive, and the pipeline shows promise. However, the increased net loss and cash burn reflect substantial investment required for commercialization and R&D. The success of ZUSDURI's commercialization and the long-term financial trajectory remain to be proven. The current financial position is solid, but the company is in an investment phase. A 'Hold' recommendation reflects the balance between significant growth potential and the inherent risks and costs associated with launching a new pharmaceutical product and advancing a clinical pipeline. Investors should monitor ZUSDURI's sales trajectory and the company's cash management closely.

Keywords

UroGen Pharma, URGN, ZUSDURI, JELMYTO, Bladder Cancer, Urothelial Carcinoma, LG-IR-NMIBC, LG-UTUC, RTGel, Oncology, Biotech, FDA Approval, Financial Results, Q2 2025, Clinical Trials, UGN-103, UGN-104, UGN-301